Additionally, the EGFR-targeted drug HLX07 plus PD-1 and chemotherapy in the treatment of unresectable or metastatic locally advanced ESCC indicated the antitumor activity, with the ORR was 55.2% (Huang et al., 2023). Here, EGFR is linked to esophageal squamous cell carcinoma.